X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (477179) 477179
Newspaper Article (30749) 30749
Newsletter (4191) 4191
Web Resource (1544) 1544
Book Chapter (1517) 1517
Dissertation (770) 770
Magazine Article (272) 272
Publication (215) 215
Book / eBook (143) 143
Trade Publication Article (129) 129
Conference Proceeding (113) 113
Government Document (104) 104
Reference (30) 30
Book Review (29) 29
Streaming Video (15) 15
Paper (3) 3
Journal / eJournal (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
humans (233832) 233832
animals (205224) 205224
kinases (136597) 136597
phosphorylation (100823) 100823
mice (94487) 94487
proteins (89716) 89716
oncology (87505) 87505
male (84291) 84291
biochemistry & molecular biology (79952) 79952
cell biology (78632) 78632
signal transduction (78049) 78049
apoptosis (77203) 77203
female (71506) 71506
cancer (67663) 67663
expression (66515) 66515
activation (61302) 61302
rats (57618) 57618
gene expression (53530) 53530
research (52310) 52310
cell line, tumor (50028) 50028
cells, cultured (46879) 46879
mutation (38782) 38782
research article (35659) 35659
cell line (35333) 35333
cell cycle (34970) 34970
signal transduction - drug effects (34583) 34583
analysis (34025) 34025
pharmacology & pharmacy (33500) 33500
multidisciplinary sciences (33170) 33170
enzyme inhibitors - pharmacology (32672) 32672
cells (31628) 31628
tumors (31087) 31087
medicine (31053) 31053
neurosciences (30782) 30782
inhibition (30713) 30713
physiological aspects (29730) 29730
protein kinases (29276) 29276
genetic aspects (28271) 28271
rodents (28243) 28243
middle aged (28008) 28008
cell proliferation (27261) 27261
health aspects (27242) 27242
physiology (26610) 26610
kinase (26522) 26522
inflammation (26509) 26509
apoptosis - drug effects (26481) 26481
biology (26418) 26418
science (24600) 24600
gene-expression (24176) 24176
metastasis (24038) 24038
adult (23693) 23693
protein kinase inhibitors - pharmacology (23583) 23583
growth (23511) 23511
immunology (23442) 23442
oxidative stress (22699) 22699
aged (22153) 22153
blotting, western (21822) 21822
dose-response relationship, drug (21720) 21720
studies (21677) 21677
care and treatment (21581) 21581
medicine, research & experimental (21535) 21535
protein (20974) 20974
cell growth (20823) 20823
cell proliferation - drug effects (20542) 20542
in-vitro (20259) 20259
proliferation (20209) 20209
rats, sprague-dawley (20076) 20076
antineoplastic agents - pharmacology (19872) 19872
chemotherapy (19729) 19729
cancer therapies (19466) 19466
genes (19366) 19366
enzymes (19316) 19316
hematology (18729) 18729
mice, inbred c57bl (18717) 18717
breast cancer (18410) 18410
metabolism (18240) 18240
protein-kinase (18218) 18218
protein-serine-threonine kinases - metabolism (18180) 18180
pathway (18135) 18135
biochemistry (18088) 18088
enzyme activation (18053) 18053
signal transduction - physiology (17905) 17905
protein-kinase-c (17818) 17818
cytokines (17775) 17775
protein binding (17761) 17761
time factors (17639) 17639
phosphorylation - drug effects (17526) 17526
immunohistochemistry (17208) 17208
activated protein-kinase (17092) 17092
nf-kappa-b (16926) 16926
map kinase (16773) 16773
transfection (16699) 16699
inhibitors (15973) 15973
in-vivo (15940) 15940
receptor (15916) 15916
tumor cells, cultured (15885) 15885
molecular sequence data (15608) 15608
medical research (15600) 15600
protein kinase c - metabolism (15599) 15599
transcription factors (15458) 15458
more...
Library Location Library Location
Library Location Library Location
X
Sort by Item Count (A-Z)
Filter by Count
Online Resources - Online (72) 72
Gerstein Science - Stacks (35) 35
Collection Dvlpm't (Acquisitions) - Vendor file (12) 12
Chemistry (A D Allen) - Stacks (3) 3
UofT at Mississauga - Stacks (3) 3
Collection Dvlpm't (Acquisitions) - Closed Orders (2) 2
Earth Sciences (Noranda) - Stacks (1) 1
Sunnybrook Health Sciences Centre - Sunnybrook Stacks (1) 1
UofT at Scarborough - Stacks (1) 1
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (512391) 512391
Japanese (2966) 2966
Chinese (2712) 2712
French (1141) 1141
German (1036) 1036
Russian (598) 598
Portuguese (313) 313
Spanish (252) 252
Korean (204) 204
Polish (162) 162
Norwegian (86) 86
Czech (85) 85
Hungarian (78) 78
Italian (63) 63
Dutch (57) 57
Turkish (34) 34
Ukrainian (29) 29
Danish (22) 22
Swedish (19) 19
Croatian (13) 13
Slovak (12) 12
Finnish (10) 10
Hebrew (6) 6
Bulgarian (4) 4
Romanian (4) 4
Serbian (4) 4
Slovenian (4) 4
Latin (3) 3
Persian (2) 2
Afrikaans (1) 1
Arabic (1) 1
Malay (1) 1
Urdu (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


2012, Methods in molecular biology, ISBN 1617793361, Volume 795., xi, 256
Book
Cellular and molecular life sciences : CMLS, ISSN 1420-9071, 2015, Volume 73, Issue 5, pp. 985 - 1001
Journal Article
Nature reviews. Cancer, ISSN 1474-1768, 2017, Volume 17, Issue 2, pp. 93 - 115
Journal Article
Cancer discovery, ISSN 2159-8290, 2017, Volume 7, Issue 4, pp. 400 - 409
Entrectinib, a potent oral inhibitor of the tyrosine kinases TRKA/B/C, ROS1, and ALK, was evaluated in two phase I studies in patients with advanced or metastatic solid tumors, including patients... 
REARRANGEMENT | ONCOGENE | ONCOLOGY | ANALOG SECRETORY CARCINOMA | LANDSCAPE | KINASE FUSIONS | SARCOMAS | ETV6-NTRK3 GENE FUSION | CRIZOTINIB | GENOMIC ALTERATIONS | CLINICAL-RESPONSE | Benzamides - pharmacokinetics | Colorectal Neoplasms - genetics | Humans | Middle Aged | Receptor, trkA - antagonists & inhibitors | Male | Receptor, trkB - genetics | Indazoles - administration & dosage | Protein Kinase Inhibitors - adverse effects | Mammary Analogue Secretory Carcinoma - genetics | Dose-Response Relationship, Drug | Benzamides - administration & dosage | Membrane Glycoproteins - antagonists & inhibitors | Receptor, trkC - genetics | Anaplastic Lymphoma Kinase | Melanoma - genetics | Colorectal Neoplasms - drug therapy | Receptor, trkB - antagonists & inhibitors | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Benzamides - adverse effects | Carcinoma, Non-Small-Cell Lung - pathology | Crizotinib | Protein Kinase Inhibitors - pharmacokinetics | Proto-Oncogene Proteins - antagonists & inhibitors | Pyridines - administration & dosage | Carcinoma, Non-Small-Cell Lung - genetics | Receptor, trkC - antagonists & inhibitors | Melanoma - pathology | Mammary Analogue Secretory Carcinoma - drug therapy | Membrane Glycoproteins - genetics | Protein Kinase Inhibitors - administration & dosage | Sequestosome-1 Protein - genetics | Pyrazoles - administration & dosage | Indazoles - pharmacokinetics | Receptor Protein-Tyrosine Kinases - genetics | Oncogene Proteins, Fusion - genetics | Melanoma - drug therapy | Adolescent | Receptor, trkA - genetics | Oncogene Proteins, Fusion - antagonists & inhibitors | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Indazoles - adverse effects | Colorectal Neoplasms - pathology | Protein-Tyrosine Kinases - antagonists & inhibitors
Journal Article
Journal of clinical oncology, ISSN 1527-7755, 2017, Volume 35, Issue 19, pp. 2193 - 2202
.... We hypothesize the programmed death-ligand 1 (PD-L1) inhibitor, durvalumab, olaparib, or cediranib combinations are tolerable and active in recurrent women's cancers... 
SENSITIVE OVARIAN-CANCER | MULTICENTER | ANTI-PD-1 | ONCOLOGY | ANTITUMOR-ACTIVITY | NIVOLUMAB | Piperazines - administration & dosage | Vascular Endothelial Growth Factor Receptor-1 - antagonists & inhibitors | Phthalazines - pharmacokinetics | Humans | Middle Aged | Antibodies, Monoclonal - adverse effects | Antineoplastic Combined Chemotherapy Protocols - pharmacokinetics | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Quinazolines - pharmacokinetics | Protein Kinase Inhibitors - adverse effects | Dose-Response Relationship, Drug | Genital Neoplasms, Female - drug therapy | Adult | Female | Quinazolines - administration & dosage | Piperazines - pharmacokinetics | Phthalazines - administration & dosage | Antibodies, Monoclonal - pharmacokinetics | Genital Neoplasms, Female - immunology | B7-H1 Antigen - immunology | Piperazines - adverse effects | Poly(ADP-ribose) Polymerase Inhibitors - administration & dosage | Genital Neoplasms, Female - metabolism | Protein Kinase Inhibitors - administration & dosage | B7-H1 Antigen - antagonists & inhibitors | Antibodies, Monoclonal - administration & dosage | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | B7-H1 Antigen - biosynthesis | Quinazolines - adverse effects | Aged | Genital Neoplasms, Female - pathology | Phthalazines - adverse effects | Lymphocytes, Tumor-Infiltrating - immunology | Index Medicus | Phase I and Clinical Pharmacology | Combined Modality | Breast Cancer | ORIGINAL REPORTS
Journal Article
The Journal of clinical investigation, ISSN 0021-9738, 2015, Volume 125, Issue 5, pp. 1780 - 1789
Kinase inhibitors have played an increasingly prominent role in the treatment of cancer and other diseases... 
MEDICINE, RESEARCH & EXPERIMENTAL | ONCOGENIC ACTIVATION | PROTEIN-KINASE | TUMOR-INFILTRATING MACROPHAGES | ADAPTIVE RESISTANCE | ACQUIRED-RESISTANCE | CLINICAL RESISTANCE | DIACYLGLYCEROL KINASES | RECEPTOR TYROSINE KINASE | IMATINIB MESYLATE | ANTITUMOR EFFICACY | Immunotherapy - methods | Apoptosis - drug effects | Humans | Substrate Specificity | Drug Resistance, Neoplasm | Neoplasm Proteins - antagonists & inhibitors | Antineoplastic Agents - therapeutic use | Antineoplastic Combined Chemotherapy Protocols - pharmacology | Neoplasms - genetics | Protein Processing, Post-Translational - drug effects | Drug Design | Antineoplastic Agents - pharmacology | Gene Expression Regulation, Neoplastic - drug effects | Phosphorylation - drug effects | Neoplasm Proteins - genetics | Molecular Targeted Therapy - methods | Neoplasms - enzymology | Gene Fusion | Enzyme Activation - drug effects | Neoplasms - drug therapy | Drug Synergism | Point Mutation | Gene Amplification | Signal Transduction - drug effects | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Oncogene Proteins, Fusion - genetics | Protein Kinase Inhibitors - therapeutic use | Oncogene Proteins, Fusion - antagonists & inhibitors | Signal Transduction - physiology | Protein Kinase Inhibitors - pharmacology | Apoptosis - physiology | Enzyme inhibitors | Physiological aspects | Research | Drug therapy | Phosphotransferases | Health aspects | Cancer | Proteins | Phosphorylation | Gene amplification | Biology | Regulation | Genomes | Mutation | Metastasis | Kinases | Phosphatase | Tumors | Review
Journal Article
American journal of clinical dermatology, ISSN 1175-0561, 06/2018, Volume 19, Issue 3, pp. 345 - 361
The development of immune checkpoint inhibitors [monoclonal antibodies targeting cytotoxic T lymphocyte-associated antigen-4 (CTLA-4... 
CELL LUNG-CANCER | CUTANEOUS ADVERSE EVENTS | UNTREATED MELANOMA | METASTATIC MELANOMA | ANTI-PD-1 THERAPY | IPILIMUMAB THERAPY | PREEXISTING AUTOIMMUNE DISORDERS | JAVELIN SOLID TUMOR | OF-THE-LITERATURE | NIVOLUMAB THERAPY | DERMATOLOGY | Index Medicus
Journal Article
Journal Article
PloS one, ISSN 1932-6203, 12/2013, Volume 8, Issue 12, p. e84700
Purpose: Although EGF receptor tyrosine kinase inhibitors (EGFR-TKI) have shown dramatic effects against EGFR mutant lung cancer, patients ultimately develop resistance by multiple mechanisms... 
CELL LUNG-CANCER | AMPLIFICATION | GENE | MULTIDISCIPLINARY SCIENCES | HEPATOCYTE GROWTH-FACTOR | PHASE-III | ACQUIRED-RESISTANCE | T790M MUTATION | RECEPTOR | GEFITINIB RESISTANCE | ERLOTINIB | Proto-Oncogene Proteins c-met - metabolism | Lung Neoplasms - drug therapy | Receptor, Epidermal Growth Factor - genetics | Phosphorylation | Humans | Lung Neoplasms - pathology | Mutation, Missense | Quinazolines | Receptor, Epidermal Growth Factor - metabolism | Female | Acrylamides - pharmacology | Pyrazoles - pharmacology | Lung Neoplasms - genetics | Lung Neoplasms - enzymology | Proto-Oncogene Proteins c-met - antagonists & inhibitors | Pyrimidines - pharmacology | Mice, SCID | Proto-Oncogene Proteins c-met - genetics | Xenograft Model Antitumor Assays | Drug Resistance, Neoplasm - genetics | Animals | Cell Line, Tumor | Receptor, Epidermal Growth Factor - antagonists & inhibitors | Mice | Protein Kinase Inhibitors - pharmacology | Pyridines - pharmacology | Amino Acid Substitution | Drug Resistance, Neoplasm - drug effects | Tyrosine | Development and progression | Genetic aspects | Epidermal growth factor | Lung cancer | Biotechnology | Laboratories | Clinical trials | Oncology | Kinases | Drug resistance | Cancer therapies | c-Met protein | Rodents | Penicillin | Protein-tyrosine kinase receptors | Inhibition | Protein-tyrosine kinase | Medical research | Epidermal growth factor receptors | Tumor cell lines | Amplification | Gene amplification | Inhibitors | Experimental design | Combined treatment | Mutation | Tumors | Cancer
Journal Article